SAVLON ANTISEPTIC CREAM
Active substance(s): CHLORHEXIDINE GLUCONATE SOLUTION / STRONG CETRIMIDE SOLUTION 40%
NAME OF THE MEDICINAL PRODUCT
Savlon Antiseptic Cream
QUALITATIVE AND QUANTITATIVE COMPOSITION
Cetrimide 0.5% w/w
Chlorhexidine Digluconate 0.1% w/w
1 gram of Savlon antiseptic cream contains 5 mg of cetrimide (0.5% w/w) and
1 mg of chlorhexidine digluconate (0.1% w/w) as the active ingredients.
Excipients with known effect:
Cetostearyl alcohol 10.00% w/w
Methyl parahydroxybenzoate (E218) 0.01% w/w
Propyl parahydroxybenzoate (E216) 0.01% w/w
For full list of excipients, see section 6.1
The cleansing and prevention of infection in all types of lesions, ranging from
minor skin disorders or blisters, to minor burns and small wounds.
Posology and method of administration
For cutaneous use only.
Apply the cream over the affected area after cleansing.
Known hypersensitivity to the product or any of its components, especially in
those with a history of possible chlorhexidine digluconate-related allergic
reactions (see sections 4.4 and 4.8).
Special warnings and precautions for use
For external use only.
Avoid contact with the eyes, middle ear, meninges and other nervous tissue.
If accidentally splashed into the eye, the open eye should be irrigated for at least 10
Keep all medicines away from children.
If symptoms persist, stop using and consult your doctor.
The product is incompatible with anionic substances (e.g. soap)
Information concerning excipients
Savlon cream contains:
Cetostearyl Alcohol: May cause local skin reactions (e.g. contact dermatitis).
Methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate
(E216):May cause allergic reactions (possibly delayed).
Chlorhexidine which is known to induce hypersensitivity, including generalised
allergic reactions and anaphylactic shock. The prevalence of Chlorhexidine
hypersensitivity is not known, but available literature suggests this is likely to
be very rare. Savlon Cream should not be administered to anyone with a
potential history of an allergic reaction to a chlorhexidine-containing
compound (see sections 4.3 and 4.8).
Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed.
Fertility, Pregnancy and lactation
There are no adequate data from the use of chlorhexidine digluconate and cetrimide in
The potential risk for humans is unknown but is most likely very low since
chlorhexidine digluconate and cetrimide are poorly absorbed following topical
It is not known whether chlorhexidine digluconate and cetrimide are excreted in
breast milk. There is no adequate data from the use of chlorhexidine and cetrimide in
breast-feeding women. However, it is unlikely that the products are excreted in breast
milk, since the products are poorly absorbed. After topical usage of the product, as a
general precaution, rinse nipples thoroughly with water before breast-feeding.
No data are available on fertility outcomes.
Effects on ability to drive and use machines
Savlon has no influence on the ability to drive and use machines.
Adverse reactions are listed below by system organ class and frequency. Frequencies
are defined as:: very common (≥1/10); common (≥1/100, <1/10); uncommon
(≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000); or not known
(cannot be estimated from the available data). Within each frequency grouping,
adverse reactions are presented in order of decreasing seriousness.
Immune system disorders
Very rare: Anaphylactic reaction
Very rare: Angioedema, urticaria
Frequency not known: Hypersensitivity including anaphylactic shock (see sections
4.3 and 4.4).
Skin and subcutaneous tissue disorders
Very rare: Skin irritation
Frequency not known: Allergic skin reactions such as dermatitis, pruritus, erythema,
eczema, rash, urticaria, skin irritation, and blisters
No investigations in children have been performed. However, frequency, type and
severity of adverse reactions in children are expected to be the same as in adults.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse reactions
via the Yellow Card Scheme at: www.mhra.gov.uk/yel1owcard.
While accidental ingestion is unlikely to cause any systemic effects due to the poor
absorption of Chlorhexidine digluconate and cetrimide, ingestion of high
concentrations may cause esophageal damage and necrosis with symptoms such as
nausea and vomiting. Cetrimide has depolarising muscle relaxant properties and toxic
symptoms include dyspnoea and cyanosis due to paralysis of the respiratory muscles,
possibly leading to asphyxia. CNS depression (sometimes preceded by excitement
and convulsions), hypotension, coma, and death may also occur.
Treatment of poisoning is symptomatic; demulcents and diluents may be given if
necessary but emesis and lavage should be avoided. Activated charcoal may be
considered if the patient presents within an hour of ingestion.
Corticosteroids may reduce oropharyngeal edema.
Chlorhexidine, combination - Pharmacotherapeutic group: Antiseptics and
disinfectants, ATC Code: D08AC52
Chlorhexidine digluconate is an effective antiseptic with a wide range of
activity against micro- organisms, including gram positive and gram negative
bacteria, fungi and viruses.
Cetrimide is a quaternary ammonium compound with surfactant and antiseptic
Chlorhexidine digluconate and cetrimide are poorly absorbed from the
gastrointestinal tract and skin.
Preclinical safety data
There is minimal systemic absorption of chlorhexidine and cetrimide
following topical administration. Preclinical data do not show genotoxic risk
for chlorhexidine digluconate. Reproductive studies with chlorhexidine
digluconate in animals have not revealed any teratogenic potential nor risk to
the foetus. No additional information is available for cetrimide.
List of excipients
Antiseptic perfume compound P2419
Chlorhexidine is incompatible with anionic substances (e.g. soap, toothpaste).
Shelf life after opening: 12 months
Special precautions for storage
Store below 25°C.
Nature and contents of container
Lacquered aluminium tube with a screw cap.
Polyethylene/aluminium/polyethylene laminate tube with a multi-layer peel-off
tamper evident seal composed of lacquer, aluminium and internal ionomer, closed
Tubes may be further packaged in unit cardboard boxes. Boxed or unboxed tubes
may be provided as items in first aid containers.
Pack sizes: 15, 30, 40, 60, and 100g.
Special precautions for disposal
Medicines should be kept out of the sight and reach of children.
MARKETING AUTHORISATION HOLDER
GlaxoSmithKline Consumer Healthcare (UK) Trading Limited,
980 Great West Road
MARKETING AUTHORISATION NUMBER(S)
DATE OF FIRST AUTHORISATION / RENEWAL OF
1 November 1997 / 04 January 2007
DATE OF REVISION OF THE TEXT
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.